ARIH2 Antibody (YA8335)

Cat. No.: HY-P88651: Data Sheet User Guide for Antibodies
FAQs
Technical Support

ARIH2 Antibody (YA8335) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ARIH2.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

ARIH2 Antibody (YA8335) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ARIH2.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 57.6 kDa

Species Reactivity

Human, Mouse, Rat

SwissProt ID

O95376

Immunogen

Human recombinant protein fragment corresponding to amino acids 201-493 of human ARIH2 produced in E.coli.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-2000

Sensitivity	Endogenous	Purity	Affinity purified
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG1

Appearance

Liquid

Formulation

Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：E3 ubiquitin-protein ligase, which catalyzes ubiquitination of target proteins together with ubiquitin-conjugating enzyme E2 UBE2L3 (PubMed:16118314, PubMed:17646546, PubMed:19340006, PubMed:24076655, PubMed:33268465, PubMed:34518685, PubMed:38418882). Acts as an atypical E3 ubiquitin-protein ligase by working together with cullin-5-RING ubiquitin ligase complex (ECS complex, also named CRL5 complex) and initiating ubiquitination of ECS substrates: associates with ECS complex and specifically mediates addition of the first ubiquitin on ECS targets (PubMed:33268465, PubMed:34518685, PubMed:38418882). The initial ubiquitin is then elongated (PubMed:33268465). E3 ubiquitin-protein ligase activity is activated upon binding to neddylated form of the cullin-5 (CUL5) component of the ECS complex (PubMed:24076655). Together with the ECS(ASB9) complex, catalyzes ubiquitination of CKB (PubMed:33268465). Promotes ubiquitination of DCUN1D1 (PubMed:30587576). Mediates 'Lys-6', 'Lys-48'- and 'Lys-63'-linked polyubiquitination (PubMed:16118314, PubMed:17646546, PubMed:19340006). May play a role in myelopoiesis (PubMed:19340006)|(Microbial infection) Following infection by HIV-1 virus, acts together with a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex) hijacked by the HIV-1 Vif protein, to catalyze ubiquitination and degradation of APOBEC3F and APOBEC3G

Subcellular Localization：Nucleus,Cytoplasm

Expression：
Tissue_Specificity: Widely expressed with higher expression in granulocytes
Induction: Up-regulated by all-trans retinoic acid (ATRA). Up-regulated during differentiation of immature blood cells toward monocytes and granulocytes

Isoforms & Post-Translational Modification：O95376: 493 amino acids, molecular weight 57819 Da.

Subunit：Interacts with (neddylated) CUL5; promoting association with cullin-5-RING ubiquitin ligase complexes (ECS complexes) (PubMed:24076655, PubMed:33268465)

Synonyms

ARI2; TRIAD1

Documentation

User Guide for Antibodies (1077 KB)